Government and private labs are springing up to accommodate expanded use of genetic evidence, but retraining existing workers.
"The bottom line is that the availability of DNA testing is increasing, and as the supply of labs increases, so does the demand," maintains Mark Stolorow, director of operations at Germantown, Md.-based Cellmark Diagnostics, a publicly traded business unit of pharmaceutical firm Zeneca Inc. that performs DNA analysis. "The demand is totally elastic."
To fill that demand personnelwise,...
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?